Compare BGLC & NDRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BGLC | NDRA |
|---|---|---|
| Founded | 2017 | 2007 |
| Country | Malaysia | United States |
| Employees | N/A | N/A |
| Industry | Medical Specialities | Biotechnology: Electromedical & Electrotherapeutic Apparatus |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.2M | 5.5M |
| IPO Year | 2019 | 2016 |
| Metric | BGLC | NDRA |
|---|---|---|
| Price | $2.14 | $4.84 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $30.00 |
| AVG Volume (30 Days) | 2.1K | ★ 19.0K |
| Earning Date | 04-14-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 45.78 | ★ 84.32 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $7,424,911.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.92 | $2.92 |
| 52 Week High | $15.19 | $11.91 |
| Indicator | BGLC | NDRA |
|---|---|---|
| Relative Strength Index (RSI) | 40.46 | 47.49 |
| Support Level | $2.14 | $4.22 |
| Resistance Level | $2.73 | $5.04 |
| Average True Range (ATR) | 0.06 | 0.50 |
| MACD | 0.00 | -0.10 |
| Stochastic Oscillator | 0.00 | 2.06 |
BioNexus Gene Lab Corp, through its wholly owned subsidiary, focuses on the sale of chemical raw materials for the manufacture of industrial, medical, appliance, aero, automotive, mechanical, and electronic industries in the Southeast Asia region. These countries include Malaysia, Indonesia, Vietnam, and other countries in Southeast Asia. In addition, the Company is in the business of developing and providing safe, effective, and non-invasive liquid biopsy tests for the early detection of biomarkers that it believes are linked to diseases to minimize treatment costs and improve patient management. Its non-invasive blood tests provide analysis of changes in RNA to detect the potential risk of different diseases.
ENDRA Life Sciences Inc is engaged in the development of Thermo Acoustic Enhanced UltraSound (TAEUS) to visualize tissue like MRI at the cost and at the point of patient care. TAEUS is designed to work in concert with around 400,000 cart-based ultrasound systems in use globally today. TAEUS is initially focused on the measurement of fat in the liver as a means to assess and monitor Non-Alcoholic Fatty Liver Disease (NAFLD) and Non-Alcoholic Steatohepatitis (NASH), chronic liver conditions that affect over one billion people globally, and for which there are no practical diagnostic tools. Beyond the liver, the firm is exploring several other clinical applications of TAEUS, including visualization of tissue temperature during energy-based surgical procedures.